ArticleBlood2022
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.
Eugen Tausch et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ArticleBlood2022
Eugen Tausch et al.PubMed ↗Publisher ↗
No numbers read from the abstract.